Table 5.

Association of ACEI/ARB use and hospital mortality stratified by typed of comorbidities and drugs.

Subgroups	N	Odds ratio (OR)		P-value for interaction
		ACEI/ARB not use	ACEI/ARB use
Coronary heart disease				0.001
Yes	3,641	Ref	0.22 (0.16–0.29)
No	11,711	Ref	0.31 (0.26–0.37)
Congestive heart failure				0.02
Yes	3,012	Ref	0.25 (0.19–0.33)
No	12,340	Ref	0.29 (0.24–0.34)
Arrthymias				<0.001
Yes	3,684	Ref	0.28 (0.22–0.35)
No	11,668	Ref	0.27 (0.22–0.33)
Cardiac shock				<0.001
Yes	251	Ref	0.15 (0.08–0.29)
No	15,101	Ref	0.29 (0.24–0.33)
COPD				0.521
Yes	1,249	Ref	0.26 (0.16–0.45)
No	14,103	Ref	0.29 (0.24–0.34)
Valvular disease				0.105
Yes	1,529	Ref	0.28 (0.19–0.41)
No	13,823	Ref	0.28 (0.24–0.33)
Respiratory failure				<0.001
Yes	3,481	Ref	0.31 (0.26–0.39)
No	11,871	Ref	0.27 (0.22–0.34)
Diabetes				0.035
Yes	4,721	Ref	0.25 (0.19–0.32)
No	10,631	Ref	0.30 (0.25–0.36)
Hypothyroidism				0.855
Yes	1,915	Ref	0.33 (0.22–0.48)
No	13,437	Ref	0.28 (0.24–0.33)
Cerebral hemorrhage				<0.001
Yes	1,042	Ref	0.21 (0.15–0.29)
No	14,310	Ref	0.27 (0.22–0.32)
AKI				<0.001
Yes	3,980	Ref	0.22 (0.17–0.28)
No	11,372	Ref	0.35 (0.28–0.40)
CKD				0.227
Yes	2,929	Ref	0.29 (0.21–0.40)
No	12,423	Ref	0.28 (0.24–0.33)
CCB				0.529
Yes	3,490	Ref	0.31 (0.24–0.41)
No	11,822	Ref	0.26 (0.22–0.36)
β blocker				0.006
Yes	7,542	Ref	0.34 (0.28–0.42)
No	7,810	Ref	0.23 (0.18–0.30)
Diuretics				0.900
Yes	4,671	Ref	0.28 (0.23–0.36)
No	10,681	Ref	0.26 (0.21–0.32)
Intravenous drugs				0.649
Yes	1,503	Ref	0.27 (0.17–0.43)
No	13,849	Ref	0.29 (0.25–0.34)